ARHGEF38

Summary

ARHGEF38 (Rho guanine nucleotide exchange factor 38, HGNC:25968) is a protein-coding gene on chromosome 4q24, encoding Rho guanine nucleotide exchange factor 38 (Q9NXL2). May act as a guanine-nucleotide releasing factor.

Predicted to enable guanyl-nucleotide exchange factor activity. Predicted to be active in cytoplasm.

Source: NCBI Gene 54848 — RefSeq curated summary.

At a glance

• Gene–disease (curated): cleft lip/palate (Moderate, GenCC) — +1 more curated relationship
• GWAS associations: 7
• Clinical variants (ClinVar): 119 total
• Phenotypes (HPO): 21
• MANE Select transcript: NM_001242729

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25968
Approved symbol	ARHGEF38
Name	Rho guanine nucleotide exchange factor 38
Location	4q24
Locus type	gene with protein product
Status	Approved
Aliases	FLJ20184
Ensembl gene	ENSG00000236699
Ensembl biotype	protein_coding
OMIM	619919
Entrez	54848

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 5 protein_coding_CDS_not_defined, 2 protein_coding

ENST00000265154, ENST00000420470, ENST00000503289, ENST00000506828, ENST00000508036, ENST00000508961, ENST00000510406

RefSeq mRNA: 2 — MANE Select: NM_001242729 NM_001242729, NM_017700

CCDS: CCDS3670, CCDS56338

Canonical transcript exons

ENST00000420470 — 14 exons

Exon	Start	End
ENSE00000801533	105552620	105552961
ENSE00001632662	105677752	105680914
ENSE00001747068	105667444	105667703
ENSE00002055485	105630898	105631045
ENSE00003473346	105589248	105589435
ENSE00003477396	105659054	105659365
ENSE00003479552	105613384	105613507
ENSE00003505366	105648549	105648682
ENSE00003527665	105636403	105636420
ENSE00003541230	105654065	105654169
ENSE00003548183	105667129	105667327
ENSE00003556160	105655603	105655722
ENSE00003594119	105645188	105645387
ENSE00003645706	105666177	105666320

Expression profiles

Bgee: expression breadth ubiquitous, 165 present calls, max score 85.17.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.8995 / max 131.2874, expressed in 135 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
49145	0.5836	107
49148	0.1442	52
49146	0.0936	46
49144	0.0404	22
49147	0.0378	22

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
body of pancreas	UBERON:0001150	85.17	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.59	gold quality
colonic epithelium	UBERON:0000397	80.33	gold quality
metanephros cortex	UBERON:0010533	78.78	gold quality
rectum	UBERON:0001052	78.28	gold quality
pancreas	UBERON:0001264	78.17	gold quality
right uterine tube	UBERON:0001302	77.52	gold quality
gall bladder	UBERON:0002110	77.50	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	77.28	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	77.03	gold quality
hair follicle	UBERON:0002073	76.88	gold quality
minor salivary gland	UBERON:0001830	75.78	gold quality
type B pancreatic cell	CL:0000169	75.58	gold quality
olfactory bulb	UBERON:0002264	75.48	gold quality
mucosa of transverse colon	UBERON:0004991	74.51	gold quality
left ventricle myocardium	UBERON:0006566	72.22	gold quality
upper lobe of left lung	UBERON:0008952	72.02	gold quality
cardiac muscle of right atrium	UBERON:0003379	71.80	gold quality
right lobe of thyroid gland	UBERON:0001119	71.30	gold quality
saliva-secreting gland	UBERON:0001044	71.19	gold quality
mouth mucosa	UBERON:0003729	71.19	gold quality
small intestine Peyer’s patch	UBERON:0003454	71.05	gold quality
islet of Langerhans	UBERON:0000006	70.49	gold quality
prostate gland	UBERON:0002367	70.47	gold quality
body of stomach	UBERON:0001161	70.41	gold quality
transverse colon	UBERON:0001157	69.77	gold quality
upper lobe of lung	UBERON:0008948	69.76	gold quality
tibialis anterior	UBERON:0001385	69.66	silver quality
stomach	UBERON:0000945	68.83	gold quality
adult mammalian kidney	UBERON:0000082	68.53	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	46.51
E-ANND-3	yes	18.30
E-GEOD-36552	no	13.07

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

40 targeting ARHGEF38, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-200A-5P	99.76	69.10	949
HSA-MIR-200B-5P	99.76	69.05	948
HSA-MIR-1255A	99.74	68.09	744
HSA-MIR-1255B-5P	99.74	68.16	741
HSA-MIR-3059-5P	99.70	69.93	2491
HSA-MIR-466	99.67	70.85	2863
HSA-MIR-548AV-5P	99.60	70.84	2107
HSA-MIR-548K	99.60	70.84	2107
HSA-MIR-3942-3P	99.57	69.03	2854
HSA-MIR-6716-5P	99.56	68.62	1244
HSA-MIR-8054	99.48	70.81	2084
HSA-MIR-208A-5P	99.42	70.83	1913
HSA-MIR-208B-5P	99.42	70.83	1952

Literature-anchored findings (GeneRIF, showing 1)

• Genome-wide analysis of copy-number variation in humans with cleft lip and/or cleft palate identifies COBLL1, RIC1, and ARHGEF38 as clefting genes. (PMID:36493769)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	arhgef38	ENSDARG00000079377
mus_musculus	Arhgef38	ENSMUSG00000040969
rattus_norvegicus	Arhgef38	ENSRNOG00000023965
caenorhabditis_elegans		WBGENE00044989

Paralogs (2): DNMBP (ENSG00000107554), ARHGEF37 (ENSG00000183111)

Protein

Protein identifiers

Rho guanine nucleotide exchange factor 38 — Q9NXL2 (reviewed: Q9NXL2)

All UniProt accessions (1): Q9NXL2

UniProt curated annotations — full annotation on UniProt →

Function. May act as a guanine-nucleotide releasing factor.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9NXL2-2	2	yes
Q9NXL2-1	1

RefSeq proteins (2): NP_001229658, NP_060170 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000219	DH_dom	Domain
IPR001452	SH3_domain	Domain
IPR004148	BAR_dom	Domain
IPR027267	AH/BAR_dom_sf	Homologous_superfamily
IPR035899	DBL_dom_sf	Homologous_superfamily
IPR036028	SH3-like_dom_sf	Homologous_superfamily
IPR051492	Dynamin-Rho_GEF	Family

Pfam: PF00621, PF03114, PF07653, PF14604

UniProt features (14 total): domain 4, compositionally biased region 3, sequence variant 2, region of interest 2, chain 1, modified residue 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NXL2-F1	75.04	0.38

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 34

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-193648	NRAGE signals death through JNK
R-HSA-416482	G alpha (12/13) signalling events
R-HSA-162582	Signal Transduction
R-HSA-193704	p75 NTR receptor-mediated signalling
R-HSA-204998	Cell death signalling via NRAGE, NRIF and NADE
R-HSA-372790	Signaling by GPCR
R-HSA-388396	GPCR downstream signalling
R-HSA-73887	Death Receptor Signaling

MSigDB gene sets: 170 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_DN, RRAGTTGT_UNKNOWN, BENPORATH_ES_WITH_H3K27ME3, chr4q24, AREB6_03, REACTOME_NRAGE_SIGNALS_DEATH_THROUGH_JNK, TGACCTY_ERR1_Q2, MEF2_02, FOXO4_01, CEBP_Q2, NKX62_Q2, E12_Q6, DBP_Q6, MEF2_Q6_01, CTAWWWATA_RSRFC4_Q2

GO Biological Process (0):

GO Molecular Function (2): guanyl-nucleotide exchange factor activity (GO:0005085), protein binding (GO:0005515)

GO Cellular Component (1): cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Signal Transduction	2
Cell death signalling via NRAGE, NRIF and NADE	1
GPCR downstream signalling	1
Death Receptor Signaling	1
p75 NTR receptor-mediated signalling	1
Signaling by GPCR	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
GTP binding	1
GDP binding	1
GTPase regulator activity	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

874 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ARHGEF38	INTS12	Q96CB8	601
ARHGEF38	ARHGEF16	Q5VV41	561
ARHGEF38	GSTCD	Q8NEC7	544
ARHGEF38	ARHGEF19	Q8IW93	540
ARHGEF38	IFRD2	Q12894	488
ARHGEF38	SH3YL1	Q96HL8	473
ARHGEF38	ARHGEF33	A8MVX0	470
ARHGEF38	ARHGAP9	Q9BRR9	456
ARHGEF38	PRR36	Q9H6K5	448
ARHGEF38	PLEC	Q15149	447
ARHGEF38	PLEKHG7	Q6ZR37	438
ARHGEF38	FCHSD1	Q86WN1	427
ARHGEF38	OR2T10	Q8NGZ9	417
ARHGEF38	NGEF	Q8N5V2	410
ARHGEF38	ASB14	A6NK59	410

IntAct

4 interactions, top by confidence:

A	B	Type	Score
ARHGEF38	ADAM10	psi-mi:“MI:0407”(direct interaction)	0.440
ARHGEF38	CLASP1	psi-mi:“MI:0915”(physical association)	0.400
ARHGEF38	CLASP1	psi-mi:“MI:0914”(association)	0.350

BioGRID (7): CLASP1 (Affinity Capture-MS), TMEM261 (Affinity Capture-MS), ARHGEF38 (Affinity Capture-RNA), ARHGEF38 (Two-hybrid), ARHGEF38 (Affinity Capture-MS), CLASP1 (Affinity Capture-MS), ARHGEF38 (Co-fractionation)

ESM2 similar proteins: A1IGU3, A1IGU4, A1IGU5, A6QP29, B1AVH7, B2RUP2, B5DFA1, D2H0G5, D3ZFJ3, O15068, O55043, P00530, P07332, P14238, P16879, P55194, P98171, Q0GNC1, Q14155, Q15052, Q27J81, Q3U5C8, Q3UMR0, Q58EX7, Q5VV41, Q5XXR3, Q5ZLR6, Q60I26, Q63406, Q64096, Q6PFY1, Q6PGG2, Q70J99, Q7TNH6, Q80TT2, Q80VK6, Q86WN1, Q8C2K1, Q8C6B2, Q8CJ00

Diamond homologs: A1IGU3, A1IGU4, A1IGU5, A1ZAY1, E7F1U2, O15068, O15085, O77775, P10569, P15498, P19878, P35991, Q08DN7, Q3LAC4, Q5DU57, Q60992, Q63406, Q69ZK0, Q70Z35, Q80VK6, Q8TCU6, Q96N96, Q9NHV9, Q9NXL2, O60229, P40995, Q1LUA6, Q5BKC9, Q5RDX5, Q64096, Q6RFZ7, Q8CHT1, Q8N5V2, Q9ES67, P52735, Q55E26, Q6TXD4, A1CEK6, A1DFN5, A2QW93

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

119 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	110
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3474 predictions. Top by Δscore:

Variant	Effect	Δscore
4:105570050:G:GT	donor_gain	1.0000
4:105570081:C:G	donor_gain	1.0000
4:105589406:G:T	donor_gain	1.0000
4:105613498:C:T	donor_gain	1.0000
4:105613501:G:GG	donor_gain	1.0000
4:105630890:T:G	acceptor_gain	1.0000
4:105631046:G:GG	donor_gain	1.0000
4:105635714:G:GT	donor_gain	1.0000
4:105645186:A:AG	acceptor_gain	1.0000
4:105645187:G:GG	acceptor_gain	1.0000
4:105645342:GACAT:G	donor_gain	1.0000
4:105645378:A:T	donor_gain	1.0000
4:105648543:TTTCA:T	acceptor_loss	1.0000
4:105648546:CA:C	acceptor_loss	1.0000
4:105648547:A:AG	acceptor_gain	1.0000
4:105648547:AG:A	acceptor_loss	1.0000
4:105648548:G:GA	acceptor_gain	1.0000
4:105648548:GTT:G	acceptor_gain	1.0000
4:105648548:GTTCT:G	acceptor_gain	1.0000
4:105648678:CACAG:C	donor_loss	1.0000
4:105648679:ACAG:A	donor_loss	1.0000
4:105648680:CAGGT:C	donor_loss	1.0000
4:105648681:AGG:A	donor_loss	1.0000
4:105648682:GGTA:G	donor_loss	1.0000
4:105648683:G:A	donor_loss	1.0000
4:105648684:T:A	donor_loss	1.0000
4:105655593:T:A	acceptor_gain	1.0000
4:105655594:G:A	acceptor_gain	1.0000
4:105655598:TTCA:T	acceptor_loss	1.0000
4:105655600:CAG:C	acceptor_loss	1.0000

AlphaMissense

5176 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:105659238:T:C	L473P	0.999
4:105677798:T:C	L732P	0.999
4:105645240:C:A	R243S	0.998
4:105645274:T:C	L254P	0.998
4:105648628:G:C	K318N	0.998
4:105648628:G:T	K318N	0.998
4:105659137:A:C	K439N	0.998
4:105659137:A:T	K439N	0.998
4:105659139:G:C	R440P	0.998
4:105659250:T:C	L477P	0.998
4:105677822:T:A	V740D	0.998
4:105677863:T:A	W754R	0.998
4:105677863:T:C	W754R	0.998
4:105677865:G:C	W754C	0.998
4:105677865:G:T	W754C	0.998
4:105677866:T:A	W755R	0.998
4:105677866:T:C	W755R	0.998
4:105677900:T:A	V766E	0.998
4:105589356:T:C	L102P	0.997
4:105645239:A:C	Q242H	0.997
4:105645239:A:T	Q242H	0.997
4:105645241:G:C	R243P	0.997
4:105648640:A:C	R322S	0.997
4:105648640:A:T	R322S	0.997
4:105659138:C:A	R440S	0.997
4:105659226:T:C	L469P	0.997
4:105677773:T:C	F724L	0.997
4:105677775:T:A	F724L	0.997
4:105677775:T:G	F724L	0.997
4:105677804:T:C	L734P	0.997

dbSNP variants (sampled 300 via entrez): RS1000021911 (4:105578198 G>A), RS1000033053 (4:105616636 G>A), RS1000078520 (4:105658930 G>A), RS1000092176 (4:105657066 T>C,G), RS1000092312 (4:105664740 G>A), RS1000111640 (4:105578606 A>G), RS1000117855 (4:105653507 G>A), RS1000143798 (4:105657687 CTTTG>C), RS1000178168 (4:105591822 A>C,T), RS1000197853 (4:105671442 G>A), RS1000203983 (4:105584092 G>A), RS1000204945 (4:105623330 G>A), RS1000206775 (4:105612929 A>G), RS1000208002 (4:105612107 G>T), RS1000257328 (4:105623057 T>C)

Disease associations

OMIM: gene MIM:619919 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
cleft lip/palate	Moderate	Autosomal dominant
autism spectrum disorder	Limited	Autosomal dominant

Mondo (2): autism spectrum disorder (MONDO:0005258), cleft lip/palate (MONDO:0016044)

Orphanet (0):

HPO phenotypes

21 total (21 of 21 shown, HPO-id order):

HPO	Term
HP:0000175	Cleft palate
HP:0000202	Orofacial cleft
HP:0000220	Velopharyngeal insufficiency
HP:0000327	Hypoplasia of the maxilla
HP:0000403	Recurrent otitis media
HP:0000405	Conductive hearing impairment
HP:0000689	Dental malocclusion
HP:0000750	Delayed speech and language development
HP:0001611	Hypernasal speech
HP:0002033	Poor suck
HP:0004395	Malnutrition
HP:0006292	Abnormality of dental eruption
HP:0006342	Peg-shaped maxillary lateral incisors
HP:0008872	Feeding difficulties in infancy
HP:0009088	Speech articulation difficulties
HP:0010294	Palate fistula
HP:0011044	Abnormal number of permanent teeth
HP:0100334	Unilateral cleft palate
HP:0100337	Bilateral cleft palate
HP:0200136	Oral-pharyngeal dysphagia
HP:0200153	Agenesis of lateral incisor

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST000542_6	Pulmonary function	5.000000e-17
GCST003264_1326	Post bronchodilator FEV1/FVC ratio	2.000000e-06
GCST004147_7	Chronic obstructive pulmonary disease	3.000000e-10
GCST004554_1	Weight	3.000000e-08
GCST006922_11	Regular attendance at a religious group	5.000000e-09
GCST007018_8	Serum bilirubin levels in metabolic syndrome	4.000000e-06
GCST007202_12	High density lipoprotein cholesterol levels	8.000000e-07

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0003892	pulmonary function measurement
EFO:0004314	forced expiratory volume
EFO:0004713	FEV/FVC ratio
EFO:0004338	body weight
EFO:0009592	social interaction measurement
EFO:0004570	bilirubin measurement
EFO:0004612	high density lipoprotein cholesterol measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

13 total (human), top 13 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol F	affects cotreatment, increases methylation	1
bisphenol A	affects cotreatment, increases methylation	1
beta-lapachone	decreases expression	1
sodium arsenite	decreases expression	1
perfluoro-n-nonanoic acid	increases expression	1
perfluorohexanesulfonic acid	increases expression	1
bisphenol S	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Benzo(a)pyrene	affects methylation, decreases methylation, increases methylation	1
Cadmium	increases abundance, decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Cadmium Chloride	decreases expression, increases abundance	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04623398	PHASE3	COMPLETED	Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
NCT04725383	PHASE3	TERMINATED	Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT05212493	PHASE3	COMPLETED	The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
NCT05361707	PHASE3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05439616	PHASE3	COMPLETED	Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
NCT06229210	PHASE3	RECRUITING	Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder